Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C48H58ClN5O9 |
Molecular Weight | 884.455 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]4(C[C@@]5([H])CN(C[C@](O)(CC)C5)CCC6=C4NC7=CC=CC=C67)C(=O)OC)[C@@]18CCN9CC=C[C@@](CC)([C@@H](OC(C)=O)[C@@]2%10OC(=O)N(CCCl)C%10=O)[C@@]89[H]
InChI
InChIKey=MMRCWWRFYLZGAE-ZBZRSYSASA-N
InChI=1S/C48H58ClN5O9/c1-7-44(59)24-29-25-47(42(57)61-6,37-31(14-19-52(26-29)27-44)30-12-9-10-13-34(30)50-37)33-22-32-35(23-36(33)60-5)51(4)39-46(32)16-20-53-18-11-15-45(8-2,38(46)53)40(62-28(3)55)48(39)41(56)54(21-17-49)43(58)63-48/h9-13,15,22-23,29,38-40,50,59H,7-8,14,16-21,24-27H2,1-6H3/t29-,38-,39+,40+,44-,45+,46+,47-,48-/m0/s1
Molecular Formula | C48H58ClN5O9 |
Molecular Weight | 884.455 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Vinzolidine (also known as LY104208), a semisynthetic vinblastine derivative that was developed as an antitumor agent. Vinzolidine participated in clinical trials phase II in the oral formulation in patients with lymphoma, particularly Hodgkin's disease. In addition, it was studied in patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. It was found significant side effects included neurotoxicity and dose-related myelosuppression. As a result, was suggested intravenous route of administration for vinzolidine could be more safely. However, the phase I trial of intravenous vinzolidine was shown no antitumor activity. The further development of this drug was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum. | 1985 |
|
Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule. | 1990 Aug |
|
Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. | 1995 |
Sample Use Guides
intravenous: the maximum tolerated dose (MTD) on this schedule was 9.0 mg/m2 with unpredictable leukopenia
oral: substantial variations in morbidity were observed among the patients, some patients receiving doses up to 45 mg/m2 without toxicity while others had severe hematologic toxicity at doses as low as 25 mg/m2.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:52:57 GMT 2023
by
admin
on
Fri Dec 15 16:52:57 GMT 2023
|
Record UNII |
533U947V6Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C932
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
||
|
NCI_THESAURUS |
C67422
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5088
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
SUB00077MIG
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
6917791
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110758
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
100000079118
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
67699-40-5
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
533U947V6Q
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
C042392
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
266-915-4
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY | |||
|
C1276
Created by
admin on Fri Dec 15 16:52:57 GMT 2023 , Edited by admin on Fri Dec 15 16:52:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |